Abstract
Overview
Introduction
The respiratory market will continue to grow with the same rate over the next
few years, with a slight dip between 2012 and 2015 due to the patent expiries
of leading products. Growth is driven by the expansion of sales in existing
classes, the launch of major new products with safety and convenience
advantages, and the results of several landmark trials.
Scope
- Indication based forecasts for asthma/COPD products and significant
pipeline drugs
- Assessment of country-specific drivers and resistors likely to impact the
market
- Future market outlook for individual products taking into account key
market events, in particular patent expiry and competitor launch dates
- Market overview by geographical area, with value analysis of clinical and
commercial factors underlying product performance
Highlights
Datamonitor expects Asthma/COPD sales in the seven major markets to grow to
about $25 billion annually by 2017, with a dip between 2012 and 2015 due to
patent expiries of key products. The ICS/LABA class is set to remain the
leading class by value throughout, while the LAMA market will experience the
strongest growth, particularly in COPD.
Novartis/Schering-Plough' s once-daily ICS/LABA product will be the top-selling
single brand in the seven major markets in 2017. However, the combined sales
of GSK' s Advair franchise (Advair/Seretide and once-daily Beyond Advair) will
dominate the asthma/COPD market over the next ten years.
The phase-out of CFC-containing inhalers in the US after 2008 will have a big
impact on the market for short-acting beta2-agonists (SABAs), increasing this
class' size significantly. The main beneficiary is expected to be Teva/UCB' s
Salamol/ProAir due to its favorable price compared with other marketed HFA
SABAs.
Reasons to Purchase
- Identify key opportunities and threats that will impact the use and uptake
of new and existing products
- Quantify the future size and scope of the asthma/COPD market and predict
the performance of key compounds
- Understand and capitalize on clinical unmet needs in the market through
both lifecycle management of marketed drugs and new product development
| 
View Cart
